

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM707677

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Saol Therapeutics Research Limited		02/09/2022	Company: IRELAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Amneal Pharmaceuticals LLC		
<b>Street Address:</b>	400 Crossing Boulevard, 3rd Floor		
<b>City:</b>	Bridgewater		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	08807		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90869741	LYVISPAH	
<b>Serial Number:</b>	90869757	BAJULTOH	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7037161180		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	703-716-1191		
<b>Email:</b>	eteas@gbpatent.com		
<b>Correspondent Name:</b>	Jeffrey H. Handelsman		
<b>Address Line 1:</b>	Greenblum & Bernstein, P.L.C.		
<b>Address Line 2:</b>	1950 Roland Clarke Place		
<b>Address Line 4:</b>	Reston, VIRGINIA 20191-1411		
<b>NAME OF SUBMITTER:</b>	Jeffrey H. Handelsman (T63787/T63789)		
<b>SIGNATURE:</b>	/Jeffrey H. Handelsman/		
<b>DATE SIGNED:</b>	02/10/2022		
<b>Total Attachments: 19</b>			
source=Trademark Assignment Agreement-Executed (05155457)#page1.tif			
source=Trademark Assignment Agreement-Executed (05155457)#page2.tif			
source=Trademark Assignment Agreement-Executed (05155457)#page3.tif			

OP \$65.00 90869741

source=Trademark Assignment Agreement-Executed (05155457)#page4.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page5.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page6.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page7.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page8.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page9.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page10.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page11.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page12.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page13.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page14.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page15.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page16.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page17.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page18.tif  
source=Trademark Assignment Agreement-Executed (05155457)#page19.tif

## INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this “Agreement”) is made effective February 9, 2022, by and among Saol International Limited, a Bermuda limited company (“SIL”), Saol Therapeutics Research Limited, an Irish limited company (“STRL”), Saol Therapeutics Inc., a Delaware corporation (“STI”), Saol International Research Limited, a Bermuda limited company (“SIRL”), Saol International Development Limited, a Bermuda limited company (“SIDL”), Emerald International Limited, a Bermuda limited company (“Emerald”), Emerald Therapeutics Research Limited, an Irish limited company (“ETRL” and, collectively with SIL, STRL, STI, SIRL, SIDL and Emerald, “Assignors” and each individually, an “Assignor”), and Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Assignee”). Assignors and Assignee are each referred to herein as a “Party” and collectively herein as the “Parties.”

### RECITALS

A. Pursuant to that certain Asset Purchase Agreement (as amended, the “Asset Purchase Agreement”), dated as of December 30, 2021, by and among Assignors and Assignee, as amended by that certain Letter Agreement, dated as of February 9, 2022, Assignors agreed to assign or cause their respective Affiliates to assign the Acquired Intellectual Property to Assignee, including the registered trademarks and service marks and applications therefor and the material unregistered trademarks, service marks and trade names set forth on Exhibit A hereto (the “Marks”), the Internet domain name registrations set forth on Exhibit B hereto (the “Domain Names”), the registered copyrights and all material unregistered copyrights, including the copyrights in and to the Marketing Materials, set forth on Exhibit C hereto (the “Copyrights”), the Product Know-How (as defined below) and the goodwill of the business associated therewith and symbolized thereby.

B. The execution and delivery of this Agreement is a requirement under the Asset Purchase Agreement.

**NOW, THEREFORE**, in consideration of the premises set forth above and in the Asset Purchase Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Definitions. All capitalized terms used but not defined herein shall have the meanings ascribed to them in the Asset Purchase Agreement. The following terms shall have the meanings set forth in this Section 1:

a. “Acquired Intellectual Property” has the meaning set forth in the Asset Purchase Agreement.

b. “Commercialize” shall mean to promote, market, distribute, sell, offer for sale, have sold and provide product support for the Product pursuant to an NDA approved by the FDA, and “Commercializing” and “Commercialization” shall have correlative meanings.

c. “Exploitation”, and related terms such as “Exploit”, shall mean the research, development, Manufacture, testing, storage, import, export, distribution, sale, use, licensing,

advertising, marketing and promotion of the Products and other Commercialization, including the outsourcing of any of the foregoing activities.

d. “Improvement” shall mean any and all improvements and enhancements, patentable or otherwise, related to a Product including, without limitation, in the manufacture, formulation, ingredients, preparation, presentation, means of delivery or administration, dosage, indication, use or packaging of Product or its active ingredient.

e. “Intellectual Property” means collectively, all rights of any nature or kind in any of the following in any jurisdiction throughout the world: (a) Patent Rights, registered trademarks and service marks and applications therefor, Internet domain name registrations and copyright registrations and applications therefor (collectively, “Registered IP”); (b) unregistered trademarks and service marks, trade names, domain names, social media names, “tags,” and “handles”, trade dress, product configurations or other marks, names, logos and slogans embodying business or product goodwill or indications of origin, all translations, adaptations, derivations and combinations thereof, and all goodwill associated with the businesses in which the foregoing are used; (c) inventions and discoveries, whether patentable or unpatentable, whether or not memorized in an invention disclosure, and whether or not reduced to practice, including articles of manufacture, business methods, compositions of matter, improvements, machines, methods, and processes and new uses for any of the preceding items, all improvements thereto; (d) unregistered copyrights, designs, mask works or other expressions and works of authorship and derivative works and translations thereof, all moral rights and visual artists’ rights in relation to the foregoing and to registered copyrights and applications therefor, (e) the right of privacy or publicity, and (f) trade secrets and know-how meeting the definition of a trade secret under the Uniform Trade Secrets Act (collectively, “Trade Secrets”) and all other Know-How.

f. “Know-How” shall mean all technical, scientific and other know-how and information, Trade Secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including high-throughput screening and other drug discovery and development technology, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed, and all improvements, whether to the foregoing or otherwise, and other discoveries, developments, inventions, and other intellectual property (whether or not confidential, proprietary, patented or patentable).

g. “Lioresal” shall mean the Product marketed by Sellers under the brand name Lioresal®, as further described on Exhibit D.

h. “Lyvispah” shall mean the Product developed by Sellers with the brand name Lyvispah®, as further described on Exhibit D.

i. “Manufacture” and “Manufacturing” shall mean all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, and shipping and

holding (prior to distribution) of the Product or any intermediate thereof, including quality assurance and quality control.

j. “Marketing Materials” means all marketing materials, research data, customer and sales information, product literature, advertising and other promotional materials and data, and training and educational materials, in each case used or held for use in the Business or that relate to the Products and/or their Exploitation, in whatever form or medium (e.g., audio, electronic, visual or print), including the materials described on Exhibit C.

k. “Patent Rights” means: (i) all patents, patent applications (including provisional applications), statutory invention registrations, utility models, inventors’ certificates in any country or supranational jurisdiction worldwide; and (ii) any substitutions, divisionals, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates, and the like of any such patents or patent applications.

l. “Product Know-How” shall mean all Know-How that is owned or purported to be owned or licensed by Assignors or any of their respective Affiliates as of the Closing Date and that relates to the Products.

m. “Products” means (i) Lioresal and Lyvispah and (ii) the pharmaceutical product under development by Assignors and their Affiliates under the name “SIL-1006”, in each case of clauses (i) and (ii), as more specifically described on Exhibit D. Products shall include (i) any Improvements to any Product referred to in the preceding sentence of this definition, including any authorized generic version of any such Product and (ii) any product sold pursuant to the Baclofen ANDA.

2. Assignment. Each Assignor hereby sells, assigns, conveys, and transfers unto Assignee and its successors and assigns, such Assignor’s entire right, title and interest in, to and under the Marks, the Domain Names, the Copyrights and the Product Know-How, including all goodwill appurtenant to, or associated with, any of the foregoing, any and all rights of renewal relating to any of the foregoing, and all past, present or existing, and future claims, causes of action, rights of recovery and rights of set-off of any kind (including the right to sue and recover for infringements or misappropriations) against any Person related to or arising from any of the foregoing, and Assignee does hereby purchase, acquire, and accept the foregoing assignment of such Acquired Intellectual Property from each Assignor.

3. Authorization. Each Assignor hereby authorizes the Director of the United States Patent and Trademark Office, the Register of the United States Copyright Office, and the empowered official of any other Governmental Authority in any jurisdiction whose duty it is to record registrations and applications for Intellectual Property to record the Marks, the Domain Names and the Copyrights held by such Assignor as the property of Assignee.

4. Further Assurances. Each Assignor shall, at Assignee’s request, for no additional consideration, promptly execute and deliver any and all instruments and documents, including confirmatory assignments suitable for recording in the relevant international jurisdictions, and take such further actions as may be reasonably necessary in order to render this Assignment fully

effective, including executing applicable domain name registrar transfer agreements, unlocking the Domain Names so as to permit their transfer, providing any authorization or other codes required for the transfer, and answering in the affirmative any request from the registrar of the Domain Names for authorization to complete the transfer.

5. Asset Purchase Agreement Controls. Nothing express or implied in this Agreement shall in any way supersede, modify, replace, amend, change, rescind, waive, limit, exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations or rights and remedies, or any of the obligations of Sellers or Buyer set forth in the Asset Purchase Agreement. In the event of any conflict or inconsistency between this Agreement and the Asset Purchase Agreement, the terms of the Asset Purchase Agreement shall govern and control.6. Miscellaneous.

- (a) Governing Law. This Agreement shall be governed by the Laws of the State of Delaware (without giving effect to any laws, rules or provisions of the State of Delaware that would cause the application of the laws, rules or provisions of any jurisdiction other than the State of Delaware) as to all matters, including matters of validity, construction, effect, performance and remedies. IN THE EVENT ANY PARTY TO THIS AGREEMENT COMMENCES ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN, WITH RESPECT TO ANY OF THE MATTERS DESCRIBED OR CONTEMPLATED HEREIN, THE PARTIES TO THIS AGREEMENT HEREBY (I) AGREE THAT ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION SHALL BE INSTITUTED IN A COURT OF COMPETENT JURISDICTION LOCATED NEW CASTLE COUNTY IN THE STATE OF DELAWARE, WHETHER A STATE OR FEDERAL COURT; (II) AGREE THAT IN THE EVENT OF ANY SUCH LITIGATION, PROCEEDING OR ACTION, SUCH PARTIES WILL CONSENT AND SUBMIT TO PERSONAL JURISDICTION IN ANY SUCH COURT DESCRIBED IN CLAUSE (I) OF THIS SECTION 4(a) AND TO SERVICE OF PROCESS UPON THEM IN ACCORDANCE WITH THE RULES AND STATUTES GOVERNING SERVICE OF PROCESS (IT BEING UNDERSTOOD THAT NOTHING IN THIS SECTION SHALL BE DEEMED TO PREVENT ANY PARTY FROM SEEKING TO REMOVE ANY ACTION TO A FEDERAL COURT IN NEW CASTLE COUNTY IN THE STATE OF DELAWARE); (III) AGREE TO WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY OBJECTION THAT THEY MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH LITIGATION, PROCEEDING OR ACTION IN ANY SUCH COURT OR THAT ANY SUCH LITIGATION, PROCEEDING OR ACTION WAS BROUGHT IN AN INCONVENIENT FORUM; (IV) AGREE THAT SERVICE OF PROCESS IN ANY LEGAL PROCEEDING MAY BE MADE BY MAILING OF COPIES THEREOF TO SUCH PARTY AT ITS ADDRESS SET FORTH IN SECTION 8.3 OF THE ASSET PURCHASE

AGREEMENT FOR COMMUNICATIONS TO SUCH PARTY; (V) AGREE THAT ANY SERVICE MADE AS PROVIDED HEREIN SHALL BE EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT; AND (VI) AGREE THAT NOTHING HEREIN SHALL AFFECT THE RIGHTS OF ANY PARTY TO EFFECT SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. EACH PARTY HERETO WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY DISPUTE IN CONNECTION WITH OR RELATING TO THIS AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN, AND AGREE TO TAKE ANY AND ALL ACTION NECESSARY OR APPROPRIATE TO EFFECT SUCH WAIVER.

- (b) Interpretation. For purposes of this Agreement, (a) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this Assignment as a whole; and (d) unless the context otherwise requires, references herein to Sections and Exhibits mean the Sections of and Exhibits attached to this Assignment. The Parties have participated jointly in the negotiation and drafting of this Assignment, and any rule of construction or interpretation otherwise requiring this Assignment to be construed or interpreted against any Party by virtue of the authorship of this Assignment shall not apply to the construction and interpretation of this Assignment. The Exhibits referred to herein shall be construed with, and as an integral part of, this Assignment to the same extent as if they were set forth verbatim herein.
- (c) Amendment. This Agreement may be amended, modified or supplemented only by written agreement of all Parties.
- (d) Waiver. No failure or delay by a Party in enforcing any of such Party’s rights under this Agreement will be deemed to be a waiver of such rights. No single or partial exercise of a Party’s rights will be deemed to preclude any other or further exercise of such Party’s rights under this Agreement. No waiver of any of a Party’s rights under this Agreement will be effective unless it is in writing and signed by such Party.
- (e) Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns, but neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party without the prior written consent of the other Party (not to be unreasonably withheld); provided that (i) either Party may assign its rights, interests and obligations under this Agreement to any Affiliate of such Party or to any Person who acquires all or substantially all of such Party’s assets, and (ii) subject to Section 7.11 of the Asset Purchase Agreement, Assignee may

assign its rights, interests and obligations under this Agreement in their entirety, but not in part, to any Person to whom it transfers all or substantially all of the Acquired Assets. In the event that either Party assigns its rights, interests and obligations hereunder without the consent of the other Party in accordance with the foregoing, the assigning Party shall promptly notify the other Party of such assignment and the identity of the assignee. This Agreement shall inure to the benefit of, and be binding upon, the Parties and their successors and permitted assigns. Any assignment of this Agreement or any of the rights, interests or obligations hereunder, in whole or in part, in contravention of this Section 4(d) shall be void ab initio.

- (f) Severability. The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or unenforceable, (a) the Parties shall use reasonable best efforts to substitute a suitable and equitable provision therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision, and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability.
  
- (g) Counterparts. This Agreement may be executed in counterparts (including using any electronic signature covered by the United States E-SIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable Law, e.g., www.docuSign.com), and such counterparts may be delivered in electronic format, including by facsimile, email or other transmission method. Such delivery of counterparts shall be conclusive evidence of the intent to be bound hereby and each such counterpart, including those delivered in electronic format, and copies produced therefrom shall have the same effect as an originally signed counterpart. To the extent applicable, the foregoing constitutes the election of the Parties to invoke any Law authorizing electronic signatures. Minor variations in the form of the signature page, including footers from earlier versions of this Agreement, shall be disregarded in determining a Party's intent or the effectiveness of such signature. No Party shall raise the use of the delivery of signatures to this Agreement in electronic format as a defense to the formation of a contract and each such Party forever waives any such defense.


[Remainder of page intentionally blank.]



IN WITNESS WHEREOF, this Intellectual Property Assignment Agreement has been duly executed and delivered by a duly authorized representative of each Party hereto as of the date first above written.

**ASSIGNORS:**

SAOL INTERNATIONAL LIMITED

By:   
Name: Kevin Insley  
Title: CEO


SAOL THERAPEUTICS RESEARCH LIMITED

By: \_\_\_\_\_  
Name: Paul Havenga  
Title: Director


SAOL THERAPEUTICS INC.

By: \_\_\_\_\_  
Name: Brian Jennette  
Title: Secretary

SAOL INTERNATIONAL RESEARCH LIMITED

By:   
Name: Kevin Insley  
Title: Director

SAOL INTERNATIONAL DEVELOPMENT LIMITED

By:   
Name: Kevin Insley  
Title: Director

*[Signature Page to Intellectual Property Assignment Agreement]*

**IN WITNESS WHEREOF**, this Intellectual Property Assignment Agreement has been duly executed and delivered by a duly authorized representative of each Party hereto as of the date first above written.

**ASSIGNORS:**

SAOL INTERNATIONAL LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: CEO

SAOL THERAPEUTICS RESEARCH LIMITED

By:   
Name: Paul Havenga  
Title: Director

SAOL THERAPEUTICS INC.

By: \_\_\_\_\_  
Name: Brian Jennette  
Title: Secretary

SAOL INTERNATIONAL RESEARCH LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

SAOL INTERNATIONAL DEVELOPMENT  
LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

*[Signature Page to Intellectual Property Assignment Agreement]*

IN WITNESS WHEREOF, this Intellectual Property Assignment Agreement has been duly executed and delivered by a duly authorized representative of each Party hereto as of the date first above written.

**ASSIGNORS:**


SAOL INTERNATIONAL LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: CEO

SAOL THERAPEUTICS RESEARCH LIMITED

By: \_\_\_\_\_  
Name: Paul Havenga  
Title: Director

SAOL THERAPEUTICS INC.

By:  \_\_\_\_\_  
Name: Brian Jennette  
Title: Secretary

SAOL INTERNATIONAL RESEARCH LIMITED


By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

SAOL INTERNATIONAL DEVELOPMENT  
LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director

*{Signature Page to Intellectual Property Assignment Agreement}*

EMERALD INTERNATIONAL LIMITED

By:   
Name: Kevin Insley  
Title: Director

EMERALD THERAPEUTICS RESEARCH  
LIMITED


By: \_\_\_\_\_  
Name: Paul Havenga  
Title: Director

*[Signature Page to Intellectual Property Assignment Agreement]*

EMERALD INTERNATIONAL LIMITED

By: \_\_\_\_\_  
Name: Kevin Insley  
Title: Director


EMERALD THERAPEUTICS RESEARCH  
LIMITED

By:  \_\_\_\_\_  
Name: Paul Havenga  
Title: Director

*[Signature Page to Intellectual Property Assignment Agreement]*

**ASSIGNEE:**

**AMNEAL PHARMACEUTICALS LLC**

By:   
Name: Anastasios G. Konidaris  
Title: Chief Financial Officer

*[Signature Page to Intellectual Property Assignment Agreement]*

**TRADEMARK**  
**REEL: 007630 FRAME: 0768**

## Exhibit A

### Marks

#### U.S. Trademark Applications and Registrations

Owner	Trademark	Serial No.	Reg. No.
Saol International Limited	LIORESAL	85215266	4006164
Saol Therapeutics Research Limited	LYVISPAH	90/869,741	
Saol Therapeutics Research Limited	BAJULTOH	90/869,757	

#### Foreign Trademark Applications and Registrations

Owner	Country	Trademark	Serial No.	Filing Date
Saol Therapeutics Research Limited	Canada	BAJULTOH	2126087	08/10/2021
Saol Therapeutics Research Limited	Canada	LYVISPAH	2126086	08/10/2021

## Exhibit B

### Domain Names

- ENLIAS.NET
- ENLIASBACLOFEN.COM
- ENLIASORALBACLOFEN.COM
- ENLIASGRANULES.COM
- ENLIASINJECTION.COM
- ENLIASBACLOFEN.NET
- ENLIASINTRAMUSCULAR.COM
- ENLIASORALBACLOFEN.NET
- ENLIASGRANULES.NET
- ENLIASINJECTION.NET
- ENLIASINTRAMUSCULAR.NET
- ENLIAS.US
- ENLIASINTRAMUSCULAR.US
- ENLIASINJECTION.US
- ENLIASGRANULES.US
- ENLIASORALBACLOFEN.US
- ENLIASBACLOFEN.US
- RXLIORESAL.COM
- LIORESALRX.COM
- LIORESALINTRATHECAL.NET
- LIORESALRX.NET
- INTRATHECALLIORESAL.COM
- LIORESALTHERAPY.COM
- INTRATHECALLIORESAL.NET
- RXLIORESAL.NET
- LIORESALTHERAPY.NET
- LIORESALINTRATHECAL.COM
- LIORESALINTRATHECAL.ORG
- LIORESALRX.ORG
- LIORESALINTRATHECAL.INFO
- RXLIORESAL.INFO
- LIORESALTHERAPY.INFO
- LIORESALRX.INFO
- INTRATHECALLIORESAL.INFO
- LIORESALTHERAPY.ORG
- RXLIORESAL.ORG
- INTRATHECALLIORESAL.ORG
- LIORESALORDERS.COM
- ORDERLIORESALINTRATHECAL.COM
- BACLOFENORDERS.COM
- ORDERLIORESAL.COM
- LIORESALINTRATHECALORDERS.COM
- LYVISPAH.COM
- BAJULTOH.COM



- SEVERESPASTICITY.BIZ
- SEVERESPASTICITY.COM
- SEVERESPASTICITY.NET
- LIORESAL.ORG
- SEVERESPASTICITY.ORG
- SEVERESPASTICITY.INFO
- ENLIAS.COM
- LIORESAL.COM
- LIORESALREFILLVIDEO.COM
- BACLOFENREFILL.COM
- ITBREFILL.COM
- LIORESALREFILL.COM
- ITBREFILL.NET
- BACLOFENREFILL.NET
- LIORESALREFILL.NET
- LIORESALREFILLVIDEO.NET
- BACLOFENREFILL.ORG
- ITBREFILL.ORG
- LIORESALREFILL.ORG
- LIORESALREFILLVIDEO.ORG
- ITBREFILL.US
- BACLOFENREFILL.US
- LIORESALREFILLVIDEO.US
- LIORESALREFILL.US
- BACLOFENGRANULES.COM
- BACLOFENGRANULE.COM
- BACLOFENORALGRANULE.COM
- BACLOFENORALGRANULES.COM

## **Exhibit C Copyrights**

### **Marketing Materials**

ST-111-1002-01\_Sadiq\_2006\_Long-term ITB in Ambulatory  
ST-111-1004-01\_Erwin\_2011\_ITB in MS  
ST-111-1005-01\_Distribution Announcement\_FINAL  
ST-111-1005-03\_Distribution Announcement\_2018  
ST-111-1005-04\_Ordering Flashcard  
ST-111-1005-04\_Ordering Flashcard\_DIGITAL ONLY  
ST-111-1006-01\_Moberg- Wolff  
ST-111-1008-01\_Saol Distribution Announcement Website  
ST-111-1009-01\_Lioresal Sterility Sales Aid  
ST-111-1009-02\_Lioresal\_Sterility\_Sales\_Aid  
ST-111-1009-02\_Sterility Sales Aid  
ST-111-1010-01\_Sonexus Web Portal Announcement Email  
ST-111-1011-01\_Saol Therapeutics Online Ordering Portal Announcement  
ST-111-1012-01\_PharmaSource Script  
ST-111-1012-01\_Sonexus Web Portal Announcement\_UN\_PW  
ST-111-1012\_01\_Portal Reminder\_Customer Email\_102616  
ST-111-1013-01\_Pharmasource Recorded ISI  
ST-111-1014-01\_ITB Best Practices\_Saulino  
ST-111-1016-01\_Wholesale Postcard  
ST-111-1018-01\_McKesson\_BannerAd  
ST-111-1020\_01\_Infographic PPT for Conventions  
ST-111-1021-01\_Lioresal Key Message Leave Behind  
ST-111-1023-01\_HCP Letter\_KD Modifier 022317  
ST-111-1027-01\_ACRM Ad\_040717  
ST-111-1028\_01\_Sintetica Launch\_Updted Ampule Sales Aid  
ST-111-1029-01\_NDC Letter  
ST-111-1030-02\_Saol Trade Announcement  
ST-111-1030\_01\_Case Study\_MD to Patient Talking Points  
ST-111-1032-01\_PHYSICIAN\_PRD

ST-111-1034-01\_CSA PRD Presentation\_USE READ ONLY  
ST-111-1035-01\_ITB\_MDT SAOL Best Practice  
ST-111-1037-01\_CSA NDC PPT  
ST-111-1038-01\_CSA NDC Email  
ST-111-1039-01\_ACRM Presentation 2017 Lioresal  
ST-111-1040-01\_Lioresal\_Wholesale\_Postcard  
ST-111-1041-01\_Brand Builder  
ST-111-1042-01\_NANS Booth Final\_121817  
ST-111-1043-01\_Guidelines Rehab Team  
ST-111-1044\_01\_SISTERS\_One-Pager  
ST-111-1045-01\_AAP Door Drop\_Final copy  
ST-111-1046-01\_Ketchum AAP Presentation  
ST-111-1050-01\_Saol\_Promotional\_Package\_Insert  
ST-111-1050-02\_Saol Packing Slip  
ST-111-1051-01\_Spaulding Letter  
ST-111-1053-01\_SISTERS Cobranded Brochure  
ST-111-1053-01\_SISTERS CoBranded Brouchure  
ST-111-1054-01\_Saol AAP 2019 Ad FINAL  
ST-111-1055-01\_Lioresal Refill Video Script with Link to Video  
ST-111-1056-01\_AAP Window Cling  
ST-111-1058-01\_AAP Saulino Presentation  
ST-111-1059-01\_Ketchum AAP Presentation  
ST-111-1065-01\_TX Medicaid Announcement  
ST-111-1066-01\_CO Pricing Piece  
ST-111-1067-01\_AAPM&R Ad  
ST-111-1068-01\_AAPMR Program Ad  
ST-111-1069-01 AAMPR Ad#2  
ST-111-1070-01\_Lioresal Refresher  
ST-111-1070-02\_Lioresal Leave Behind\_DIGITAL ONLY  
ST-111-1071-01\_Saol MDT Slides AAPMR  
ST-111-1072-01\_Schiess Reprint  
ST-111-1073-01\_PT Unbranded Leave Behind  
ST-111-1074-01\_PT Unbranded Slide Deck\_USE READ ONLY

ST-111-1075-01\_AAP 2020 Presentation  
ST-111-1076-01\_Schiess Email Template  
ST-111-1077-01\_Field Communications Flowonix Backgrounder  
ST-111-1078-01\_CSA Field Presentation  
ST-111-1079-04\_Saol MDT Collaboration Presentation  
ST-111-1080-01\_Choosing Lioresal Intrathecal (baclofen injection)  
ST-111-1081-01\_Ordering Lioresal Intrathecal (baclofen injection)  
ST-111-1082-01\_Lioresal Intrathecal (baclofen injection) Support and Service  
ST-111-1083-01\_PT Inservice  
ST-111-1084-01-Saol Therapeutics Refill and Demonstration and Support  
ST-111-1085-01\_Customer Email Update Template  
ST-111-2003-01\_Brand Builder\_Saol\_MDT  
ST-111-2004-01\_ITB Cobranded Brochure  
ST-111-2005-01\_Screening Trial Q&A  
ST-111-3001\_3002\_3005\_3006\_Booth Panes and Images  
ST-111-3003\_3004\_3010-01\_Booth Images and Panes  
ST-111-3007-01\_Spasticity Infographic  
ST-111-3009-02\_Pt ISI\_Branded  
ST-111-3009-04\_Saol\_Patient ISI  
ST-111-3011-01\_Lioresal Website  
ST-111-3014-01\_Cobranded Screening Test Brochure

**Exhibit D  
Products**

- Lioresal® Intrathecal (NDA 020075), also known as Intrathecal Baclofen Therapy (ITB) is a treatment to help manage severe spasticity and works by delivering precise doses of baclofen into the fluid surrounding the spinal cord.
- Lyvispah (IND 140719; NDA 215422) is an oral granule formulation of baclofen indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
- SIL-1006 (IND 140290) is an intramuscular formulation of baclofen that is being studied for the anticipated indication of temporary treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity when oral or intrathecal forms of administration are unavailable.